Thrombolytic Agent for Stroke

Phase-Based Progress Estimates
Michael E. DeBakey VA Medical Center, Houston, TX
Stroke+6 More
Thrombolytic Agent - Drug
All Sexes
What conditions do you have?

Study Summary

Acute stroke afflicts nearly 700,000 patients in the US and is the number 3 cause of death. Only 2-9% of this large number is treated with t-PA if they arrive within 4.5 hours. An equally small percentage of patients with large vessel occlusion undergo thrombectomy. The thrombectomy patients may or may not receive t-PA. Some of these patients rarely receive intravenous GPIIB/IIIa inhibitors. Many lines of evidence suggest that GP IIb/IIIa inhibitors, a class of FDA approved potent platelet inhibitors that have been used extensively along with heparin for acute coronary syndromes (heart attacks) and unstable angina (chest pain), may be safe enough to give in these circumstances.

Eligible Conditions

  • Stroke
  • Cerebrovascular accident

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Ninety days

Ninety days
Ninety day functional outcomes

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Measurement of Platelet function
1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Thrombolytic Agent · No Placebo Group · Phase 1 & 2

Measurement of Platelet function
Experimental Group · 1 Intervention: Thrombolytic Agent · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Thrombolytic Agent

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: ninety days
Closest Location: Michael E. DeBakey VA Medical Center · Houston, TX
Photo of Houston 1Photo of Houston 2Photo of Houston 3
2007First Recorded Clinical Trial
1 TrialsResearching Stroke
50 CompletedClinical Trials

Who is running the clinical trial?

Baylor College of MedicineLead Sponsor
910 Previous Clinical Trials
5,981,736 Total Patients Enrolled
4 Trials studying Stroke
1,198 Patients Enrolled for Stroke

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be 18 years or older to participate in this study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.